Age is an important prognostic factor of papillary thyroid carcinoma (PTC). In this study, we investigated the prognosis and prognostic factors of PTC in patients younger than 20 years. We enrolled 110 patients who underwent initial surgery at Kuma Hospital between 1987 and 2008. Tumor size > 4 cm, metastatic node ≥ 3 cm, and significant extrathyroid extension were more frequently detected in 8 patients with distant metastasis at diagnosis than in 102 patients without distant metastasis. Ten- and 20-year lymph node recurrence-free survival (LN-RFS) and distant recurrence-free survival (DRFS) rates were 84 and 80%, and 95 and 89%, respectively. Metastatic node ≥ 3 cm, age ≤ 16 years, tumor size > 4 cm, and male gender affected LN-RFS, and the former two had an independent prognostic value in multivariate analysis. Metastastic node ≥ 3 cm, significant extrathyroid extension, age ≤ 16 years, tumor size > 4 cm, and a male gender predicted a poor DRFS, and the former two were independent prognostic factors. To date, only 2 patients have died of PTC. These findings suggest that, in the subset of PTC patients younger than 20 years, metastatic node ≥ 3 cm, significant extension, and age ≤ 16 were important signs of aggressiveness of carcinoma, and careful treatment is necessary for patients with these characteristics, although the cause-specific survival was excellent.

Download full-text PDF

Source
http://dx.doi.org/10.1507/endocrj.ej12-0086DOI Listing

Publication Analysis

Top Keywords

node ≥
16
prognostic factors
12
tumor size
12
metastatic node
12
age ≤
12
prognosis prognostic
8
papillary thyroid
8
thyroid carcinoma
8
patients
8
ptc patients
8

Similar Publications

Purpose: In metastatic castration-resistant prostate cancer (mCRPC), some patients show low/absent PSMA expression in tumour lesions on positron emission tomography (PET) scans, indicating heterogeneity and heightened risk of non-response to PSMA-RLT (radioligand therapy). Imaging cancer-associated fibroblasts and glucose uptake may further characterise tumour heterogeneity in mCRPC patients. Here, we aimed to evaluate tumour heterogeneity and its potential implications for management in mCRPC patients assessed for PSMA-RLT using [Ga]Ga-FAPI-46, 2-[F]FDG and [Ga]Ga-/[F]F-PSMA-11/-1007 PET.

View Article and Find Full Text PDF
Article Synopsis
  • PSMA-PET, introduced in 2012, has significantly improved prostate cancer staging, leading to the development of the PROMISE criteria for standardized imaging reports.
  • This study analyzed data from a large cohort of prostate cancer patients across multiple German hospitals to assess the prognostic value of PROMISE staging in comparison to existing clinical risk assessment models.
  • The findings from 2,414 patients revealed that PPP staging had performance metrics comparable to established clinical risk scores, thus highlighting its potential usefulness in predicting overall survival outcomes.
View Article and Find Full Text PDF

Antibody-drug conjugates (ADCs) represent a novel type of targeted cancer therapy combining the specificity of monoclonal antibodies with the cytotoxicity of conventional chemotherapy. Recently, ADCs have demonstrated practice-changing efficacy across diverse solid cancers. The anti-NECTIN-4 ADC enfortumab vedotin (EV) has just been approved for patients with urothelial cancer and is currently under investigation for patients with castration-resistant prostate cancer (CRPC e.

View Article and Find Full Text PDF
Article Synopsis
  • * The design of a new NCI-sponsored randomized trial aims to determine the best chemotherapy regimen for patients who achieve a clinical complete response (cCR) after TNT, potentially allowing for a "watch and wait" strategy instead of immediate surgery.
  • * The trial will enroll up to 760 patients with specific LARC criteria and will evaluate the effectiveness of long-course chemoradiation followed by different consolidation chemotherapy regimens, with patient outcomes being monitored over time.
View Article and Find Full Text PDF
Article Synopsis
  • - The study reviews the "pentafecta" criteria for reporting outcomes following radical cystectomy (RC), originally encompassing five specific health measures; it has since been modified to focus more on complications and cancer recurrence.
  • - A total of 12 studies involving nearly 5,000 patients were analyzed, revealing that only 34% achieved all pentafecta goals, with major complications and insufficient lymph node removal being significant barriers.
  • - The research indicates that achieving pentafecta is linked to better long-term cancer outcomes and quality of life, but limitations include the retrospective nature of studies and generally short follow-up periods.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!